Joseph F Costello
Overview
Explore the profile of Joseph F Costello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
149
Citations
15146
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wang Q, Wang J, Mathur R, Youngblood M, Jin Q, Hou Y, et al.
Sci Adv
. 2025 Mar;
11(11):eadn2830.
PMID: 40073147
Glioblastoma (GBM) is the most prevalent malignant brain tumor with poor prognosis. Although chromatin intratumoral heterogeneity is a characteristic feature of GBM, most current studies are conducted at a single...
2.
Rodriguez Almaraz E, Guerra G, Al-Adli N, Young J, Dada A, Quintana D, et al.
Neurooncol Adv
. 2025 Mar;
7(1):vdaf024.
PMID: 40051658
Background: Isocitrate dehydrogenase (IDH)-mutant astrocytomas represent the most frequent primary intraparenchymal brain tumor in young adults, which typically arise as low-grade neoplasms that often progress and transform to higher grade...
3.
Kwok D, Stevers N, Etxeberria I, Nejo T, Colton Cove M, Chen L, et al.
Nature
. 2025 Feb;
639(8054):463-473.
PMID: 39972144
T cell-based immunotherapies hold promise in treating cancer by leveraging the immune system's recognition of cancer-specific antigens. However, their efficacy is limited in tumours with few somatic mutations and substantial...
4.
Lucas C, Al-Adli N, Young J, Gupta R, Morshed R, Wu J, et al.
Neuro Oncol
. 2024 Nov;
27(1):89-105.
PMID: 39560080
Background: Despite recent advances in the biology of IDH-wildtype glioblastoma, it remains a devastating disease with median survival of less than 2 years. However, the molecular underpinnings of the heterogeneous...
5.
Kwok D, Okada H, Costello J
Nat Genet
. 2024 Sep;
56(9):1770-1771.
PMID: 39223317
No abstract available.
6.
Schupp P, Shelton S, Brody D, Eliscu R, Johnson B, Mazor T, et al.
Cancers (Basel)
. 2024 Jul;
16(13).
PMID: 39001492
Tumors may contain billions of cells, including distinct malignant clones and nonmalignant cell types. Clarifying the evolutionary histories, prevalence, and defining molecular features of these cells is essential for improving...
7.
Beccari S, Mohamed E, Voong V, Hilz S, Lafontaine M, Shai A, et al.
Mod Pathol
. 2024 Apr;
37(6):100488.
PMID: 38588881
Biomarker-driven therapeutic clinical trials require the implementation of standardized, evidence-based practices for sample collection. In diffuse glioma, phosphatidylinositol 3 (PI3)-kinase/AKT/mTOR (PI3/AKT/mTOR) signaling is an attractive therapeutic target for which window-of-opportunity...
8.
Nejo T, Wang L, Leung K, Wang A, Lakshmanachetty S, Gallus M, et al.
Sci Rep
. 2024 Mar;
14(1):6362.
PMID: 38493204
Despite advancements in cancer immunotherapy, solid tumors remain formidable challenges. In glioma, profound inter- and intra-tumoral heterogeneity of antigen landscape hampers therapeutic development. Therefore, it is critical to consider alternative...
9.
Stevers N, Costello J
Neuro Oncol
. 2024 Mar;
26(6):1025-1026.
PMID: 38466631
No abstract available.
10.
Mathur R, Wang Q, Schupp P, Nikolic A, Hilz S, Hong C, et al.
Cell
. 2024 Jan;
187(2):446-463.e16.
PMID: 38242087
Treatment failure for the lethal brain tumor glioblastoma (GBM) is attributed to intratumoral heterogeneity and tumor evolution. We utilized 3D neuronavigation during surgical resection to acquire samples representing the whole...